Targeting CD24 as a novel immunotherapy for solid cancers

Yang, Yan; Zhu, Guangming; Yang, Li; Yang, Yun

doi:10.1186/s12964-023-01315-w

Cited by 12 publications

(4 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, CD24 has attracted a lot of attention as a potential target for drug therapy against tumor cells or tumor stem cells. Several oncology clinical trials worldwide are currently testing the clinical efficacy of anti-CD24-based tumor therapy, and many more are registered on ClinicalTrials.gov (10).…”

Section: Discussionmentioning

confidence: 99%

“…This interaction promotes immune escape of tumor cells and creates a new immune checkpoint in the form of a “don’t eat me” signal ( 7 , 8 ). Therefore, CD24 has become a potential therapeutic target for cancer treatments, including antibody drugs, gene therapy, chimeric antigen receptor (CAR) T cell therapy, and more ( 9 , 10 ). In addition, anti-tumor therapy targeting CD24 can also affect the tumor microenvironment and promote the immune system’s attack on the tumor, so CD24 may also be a target for immunotherapy ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Checkpoint CD24 function on tumor and immunotherapy

Huang,

Zhang,

Wei

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack. Although the use of CD24 as a immune checkpoint receptor target for cancer immunotherapy is still in its early stages, clinical trials have shown promising results. Monoclonal antibodies targeting CD24 have been found to be well-tolerated and safe. Other preclinical studies are exploring the use of chimeric antigen receptor (CAR) T cells, antibody-drug conjugates, and gene therapy to target CD24 and enhance the immune response against tumors. In summary, this review focuses on the role of CD24 in the immune system and provides evidence for CD24 as a promising immune checkpoint for cancer immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Checkpoint CD24 function on tumor and immunotherapy

Huang,

Zhang,

Wei

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The Nodal Involvement Signature (NIS) comprises CD24, CD31 and CD40 with a combined ROC curve AUC of 0.827 referring to nodal involvement. CD24 is a small adhesion protein implicated in tumor immune evasion, cancer aggressiveness and remarkably, also into epithelial to mesenchymal transition (EMT) [ 19 , 20 ]. CD31 has been recognized as a cancer migration marker contributing to the invasiveness and associated with bad prognosis in different cancer subtypes [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer

Bocchetti,

Luce,

Iannarone

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Background Exosomes are nanosized vesicles released from all cells into surrounding biofluids, including cancer cells, and represent a very promising direction in terms of minimally invasive approaches to early disease detection. They carry tumor-specific biological contents such as DNA, RNA, proteins, lipids, and sugars, as well as surface molecules that are able to pinpoint the cellular source. By the above criteria, exosomes may be stratified according to the presence of tissue and disease-specific signatures and, due to their stability in such biofluids as plasma and serum, they represent an indispensable source of vital clinical insights from liquid biopsies, even at the earliest stages of cancer. Therefore, our work aimed to isolate and characterize LCa patients’ derived exosomes from serum by Flow Cytometry in order to define a specific epitope signature exploitable for early diagnosis. Methods Circulating exosomes were collected from serum collected from 30 LCa patients and 20 healthy volunteers by the use of antibody affinity method exploiting CD63 specific surface marker. Membrane epitopes were then characterized by Flow cytometry multiplex analysis and compared between LCa Patients and Healthy donors. Clinical data were also matched to obtain statistical correlation. Results A distinct overexpression of CD1c, CD2, CD3, CD4, CD11c, CD14, CD20, CD44, CD56, CD105, CD146, and CD209 was identified in LCa patients compared to healthy controls, correlating positively with tumor presence. Conversely, CD24, CD31, and CD40, though not overexpressed in tumor samples, showed a significant correlation with nodal involvement in LCa patients (p < 0.01). Conclusion This approach could allow us to set up a cost-effective and less invasive liquid biopsy protocol from a simple blood collection in order to early diagnose LCa and improve patients’ outcomes and quality of life. Graphical Abstract

show abstract

“…Nevertheless, ongoing research aims to enhance the efficacy of CD24-targeting therapies and minimize potential toxic effects. [75] [76] Doublecortin-like kinase 1 (DCLK1) represents a protein recognized as a marker for tumor stem cells in gastrointestinal tract, pancreatic, and human cells associated with colorectal cancer. DCLK1 is linked to elevated.…”

Section: Introductionmentioning

confidence: 99%

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

Parichehreh,

Kiaei,

Boush

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundMalignant neoplasm of the pancreas (MNP), a highly lethal illness with bleak outlook and few therapeutic avenues, entails numerous cellular transformations. These include irregular proliferation of ductal cells, activation of stellate cells, initiation of epithelial-to-mesenchymal transition, and changes in cell shape, movement, and attachment. Discovering potent drug cocktails capable of addressing the genetic and protein factors underlying pancreatic cancer’s development is formidable due to the disease’s intricate and varied nature.MethodIn this study, we introduce a fresh model utilizing Graph Attention Networks (GATs) to pinpoint potential drug pairings with synergistic effects for MNP, following the RAIN protocol. This protocol comprises three primary stages: Initially, employing Graph Neural Network (GNN) to suggest drug combinations for disease management by acquiring embedding vectors of drugs and proteins from a diverse knowledge graph encompassing various biomedical data types, such as drug-protein interactions, gene expression, and drug-target interactions. Subsequently, leveraging natural language processing to gather pertinent articles from clinical trials incorporating the previously recommended drugs. Finally, conducting network meta-analysis to assess the relative effectiveness of these drug combinations.ResultWe implemented our approach on a network dataset featuring drugs and genes as nodes, connected by edges representing their respective p-values. Our GAT model identified Gemcitabine, Pancrelipase Amylase, and Octreotide as the optimal drug combination for targeting the human genes/proteins associated with this cancer. Subsequent scrutiny of clinical trials and literature confirmed the validity of our findings. Additionally, network meta-analysis confirmed the efficacy of these medications concerning the pertinent genes.ConclusionBy employing GAT within the RAIN protocol, our approach represents a novel and efficient method for recommending prominent drug combinations to target proteins/genes associated with pancreatic cancer. This technique has the potential to aid healthcare professionals and researchers in identifying optimal treatments for patients while also unveiling underlying disease mechanisms.HighlightsGraph Attention Networks (GATs) used to recommend drug combinations for pancreatic cancerRAIN protocol applied to extract relevant information from clinical trials and literatureGemcitabine, Pancrelipase Amylase, and Octreotide identified as optimal drug combinationNetwork meta-analysis confirmed the effectiveness of the drug combination on gene targetsNovel and efficient method for drug discovery and disease mechanism elucidationAbstract Figure

show abstract

Targeting CD24 as a novel immunotherapy for solid cancers

Cited by 12 publications

References 116 publications

Checkpoint CD24 function on tumor and immunotherapy

Checkpoint CD24 function on tumor and immunotherapy

Exosomes multiplex profiling, a promising strategy for early diagnosis of laryngeal cancer

Graph Attention Networks for Drug Combination Discovery: Targeting Pancreatic Cancer Genes with RAIN Protocol

Contact Info

Product

Resources

About